Browse EX-10 agreements

Senior Secured Convertible Note

THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY THIS SECURITY.

Original Issue Date: September 14, 2026	Funding Amount	$ 1,575,000
Final Maturity Date: March 1, 2027	Original Principal Amount:	$ 2,126,250

CDT EQUITY INC.

…

Execution Version

ROUNDTABLE STRATEGIC PLATFORM AGREEMENT

PARTNER		Paradium.AI, Inc. f/k/a The Arena Group Holdings, Inc.
EFFECTIVE DATE:		Upon Completion of Certain Conditions Precedent
ADDITIONAL TERMS:		All Exhibits

…

Execution Version

ROUNDTABLE STRATEGIC PLATFORM AGREEMENT

PARTNER		Paradium.AI, Inc. f/k/a The Arena Group Holdings, Inc.
EFFECTIVE DATE:		Upon Completion of Certain Conditions Precedent
ADDITIONAL TERMS:		All Exhibits

…

LENNOX INTERNATIONAL INC.

Long-Term Incentive Award Agreement

U.S. Employees – Vice President and Above

THIS AGREEMENT (“Agreement”) is made as of ______________ (the “Date of Grant”), by and between Lennox International Inc., a Delaware corporation (the “Company”), and __________ (“Participant”).

The Company has adopted the Lennox International Inc. 2019 Equity and Incentive Compensation Plan (as amended and restated from time to time, the “Plan”), the terms of which are incorporated by reference and made a part of this Agreement, for the benefit of eligible employees, Directors, and certain other service providers of the Company and its Subsidiaries (together, “LII”). Capitalized terms used and not otherwise defined in this Agreement have the meanings set forth in the Plan.

…

** **

AMENDMENT NO. 7 TO LOAN AND SECURITY AGREEMENT

THIS AMENDMENT NO. 7 TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated September 17, 2026 (the “Amendment No. 7 Effective Date”), is by and among FLUX POWER, INC., a California corporation (“Flux”), and FLUX POWER HOLDINGS, INC., a Nevada corporation (“Holdings” and, together with Flux, individually and collectively, jointly and severally, the “Borrower”), and GIBRALTAR BUSINESS CAPITAL, LLC, a Delaware limited liability company (the “Lender”).

W I T N E S S E T H:

…

** **

AMENDMENT NO. 8 TO THE
ADIAL PHARMACEUTICALS, INC.
2017 EQUITY INCENTIVE PLAN

This amendment (the “Amendment”) to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Plan, as amended (the “Plan”), is hereby adopted this 17th day of September, 2026, by Adial Pharmaceuticals, Inc. (the “Company”). All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings set forth in the Plan.

** **

WITNESSETH:

** **

WHEREAS, the Company adopted the Plan for the purposes set forth therein; and

** **

WHEREAS, pursuant to Section 15 of the Plan, the Board of Directors has the right to amend the Plan with respect to certain matters, provided that any material increase in the number of Shares available under the Plan shall be subject to stockholder approval; and

** **

WHEREAS, the Board of Directors has approved and authorized this Amendment to the Plan and has recommended that the stockholders of the Company approve this Amendment; and

** **

…

** **

ADIAL PHARMACEUTICALS, INC.

** **

2026 EQUITY INCENTIVE PLAN

** **

ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 12, 2026

** **

APPROVED BY THE STOCKHOLDERS: SEPTEMBER 17, 2026

** **

1. GENERAL

** **

(a) Successor to Prior Plan. The Plan is the successor to the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; and (ii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan. All Awards granted under this Plan will be subject to the terms of this Plan.

** **

(b) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.

** **

…

** **

ADIAL PHARMACEUTICALS, INC.

** **

2026 EMPLOYEE STOCK PURCHASE PLAN

** **

ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 12, 2026

** **

APPROVED BY THE STOCKHOLDERS: September 17, 2026

** **

1. GENERAL; PURPOSE.

** **

**(a) **The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan.

** **

…

FORM OF LOCK-UP AGREEMENT

LOCK-UP AGREEMENT

THIS LOCK-UP AGREEMENT (this “Agreement”) is made and entered into as of ________, 2026, by and among (i) ChampionsGate Acquisition Corp, a Cayman Islands exempted company (“Purchaser”), (ii) FutureMain AI Technologies Ltd., a Cayman Islands exempted company (“Pubco”), (iii) Futuremain Co., Ltd., a Korean company (the “Company”), and (iv) the undersigned (“Holders” and each a “Holder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Business Combination Agreement.

WHEREAS, on **________, 2026, Purchaser, the Company, and other parties thereto entered into that certain Business Combination Agreement (as amended from time to time in accordance with the terms thereof, the “Business Combination Agreement”); and

…

COMMON STOCK PURCHASE AGREEMENT

Dated as of September 18, 2026

by and between

BIOSTEM TECHNOLOGIES, INC.

and

ROTH PRINCIPAL INVESTMENTS, LLC

---

Table of Contents

Page

Article I DEFINITIONS		1

…

REGISTRATION RIGHTS AGREEMENT

ThisREGISTRATION RIGHTS AGREEMENT(this “Agreement”), dated as of September 18, 2026, is by and between Roth Principal Investments, LLC, a Delaware limited liability company (the “Investor”), and BioStem Technologies, Inc., a Florida corporation (the “Company”).

RECITALS

A. The Company and the Investor have entered into that certain Common Stock Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which the Company may issue, from time to time, to the Investor up to the lesser of (i) $40,000,000 in aggregate gross purchase price of newly issued shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), and (ii) the Exchange Cap (to the extent applicable under Section 3.5 of the Purchase Agreement), as provided for therein.

…

SIXTH STREET LENDING PARTNERS

$750,000,000

6.500% Notes due 2031

Purchase Agreement

September 14, 2026

BofA Securities, Inc.

One Bryant Park

New York, New York 10036

As Representative of the

several Initial Purchasers listed

in Schedule 1 hereto

Ladies and Gentlemen:

Sixth Street Lending Partners, a Delaware statutory trust (the “Company”), proposes to issue and sell to the several Initial Purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representative (the “Representative”), $750,000,000 aggregate principal amount of 6.500% Notes due 2031 (the “Notes”).

…